908 Devices (NASDAQ:MASS) reached a major financial milestone in the fourth quarter, reporting positive adjusted EBITDA and cash flow for the first time as the company’s high-margin recurring revenue began to scale.
The Boston-based specialist in handheld chemical analysis reported fourth-quarter revenue of $17.4 million, a 21% increase over the same period in 2024.
For the full year 2025, revenue climbed 18% to $56.2 million.
The growth was spearheaded by the company’s "razor-and-blade" model, with annual recurring revenue from consumables and service contracts rising 22% to $19.5 million, now accounting for 35% of total sales.
The shift toward a more service-oriented revenue mix significantly bolstered the bottom line.
Adjusted gross margin for the fourth quarter reached 57%, a 530-basis point improvement over the prior year.
This efficiency gain allowed 908 Devices to deliver net income from continuing operations of $4.4 million and achieve a positive Adjusted EBITDA of $0.7 million, meeting a key long-term goal set by management.
The company’s technology, which miniaturizes complex mass spectrometry into rugged, handheld devices, has seen expanded adoption in forensic drug detection and bioprocessing monitoring.
By providing lab-quality results in the field, 908 Devices has successfully carved out a niche within the broader analytical instrument market.
Meanwhile, 908 Devices ended 2025 with a robust balance sheet, maintaining a cash position of $113 million.
With no debt and a now-proven path to profitability, the company is well-positioned to reinvest in its product pipeline, particularly in its safety and defense verticals, where government contracts for chemical identification tools remain a steady growth driver.